The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Published:2017-12-26 Issue:2 Volume:67 Page:549-559
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Loomba Rohit¹,Lawitz Eric²,Mantry Parvez S.³,Jayakumar Saumya⁴,Caldwell Stephen H.⁵,Arnold Hays⁶,Diehl Anna Mae⁷,Djedjos C. Stephen⁸,Han Ling⁸,Myers Robert P.⁸,Subramanian G. Mani⁸,McHutchison John G.⁸,Goodman Zachary D.⁹,Afdhal Nezam H.¹⁰,Charlton Michael R.¹¹,

Affiliation:

1. University of California at San DiegoSan Diego CA

2. Texas Liver InstituteUniversity of Texas Health San AntonioSan Antonio TX

3. The Liver Institute at Methodist DallasDallas TX

4. University of CalgaryCalgary AB Canada

5. University of VirginiaCharlottesville VA

6. Gastroenterology Consultants of San AntonioSan Antonio TX

7. Duke Clinical Research InstituteDurham NC

8. Gilead Sciences, Inc.Foster City CA

9. Inova Fairfax HospitalFalls Church VA

10. Beth Israel Deaconess Medical CenterHarvard Medical SchoolBoston MA

11. Intermountain Medical CenterSalt Lake City UT

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.29514

Reference44 articles.

1. Design and validation of a histological scoring system for nonalcoholic fatty liver disease

2. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality

3. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

4. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

5. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

Cited by 441 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease;Hormones;2024-08-07

3. AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases;Nature Medicine;2024-08-07

4. Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease;Journal of Clinical and Translational Hepatology;2024-07-31

5. Potential therapeutic strategies for MASH: from preclinical to clinical development;Life Metabolism;2024-07-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3